-transparent.png){kind=logo}
The clinical relevance of regular serum aluminium monitoring in dialysis patients was investigated in a multicentre study by 6-monthly determination of the serum aluminium during 4 consecutive years. In a group totalling 1193 patients, a striking decrease of mean serum aluminium was observed the last 2 years of the study. This phenomenon was accompanied by a substantial reduction of the prescribed dose of aluminium hydroxide (Al(OH)3) and its partial replacement by calcium carbonate (CaCO3) and/or magnesium hydroxide (Mg(OH)2). Under this policy serum phosphate control remained satisfactory. In all the centres, water treatment was found to be adequate, yielding dialysate aluminium around 2 micrograms/l. Dialysis patients with clinically overt liver disease showed a significantly greater median serum aluminium concentration than that observed in a control dialysis population. Compared to the latter group, the median serum aluminium concentration of dialysis patients with diabetes mellitus did not differ significantly. Results further indicated that patients with biopsy-proven osteomalacia presented a significantly greater median serum aluminium compared to that of patients without osteomalacia. We demonstrated that a serum aluminium of 60 micrograms/l provides a relatively sensitive (82%) and specific (86%) index for the detection of aluminium-related bone disease (ARBD). Provided the aluminium determinations are performed by a qualified laboratory, serum monitoring in dialysis patients (a) allows the safer use of aluminium-containing phosphate binders, and (b) is of value in the diagnosis of overload/toxicity.
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
January 1993,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
October 1980,
Lancet (London, England),
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
January 1992,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
March 1983,
Lancet (London, England),
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
June 2023,
Biological trace element research,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
January 1982,
European neurology,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
January 1989,
Annali dell'Istituto superiore di sanita,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
September 1998,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
October 1986,
Clinica chimica acta; international journal of clinical chemistry,
P C D'Haese, and
J P Clement, and
M M Elseviers, and
L V Lamberts, and
F L Van de Vyver, and
W J Visser, and
M E De Broe
July 1988,
Lancet (London, England),
